SuperworthHCA Healthcare, Inc. HCA
Medical - Care Facilities, Healthcare
$439.17
+1.61%
- Market cap
- $95.1B
- PE
- 14.7×
- 10y median 13.8×
- Forward PE
- Price to sales
- 1.2×
- EV/EBIT
- 12.1×
- Revenue, 12 months
- $78B
- +7% on a year ago
- Net margin
- 8.8%
- Free cash flow yield
- 6.3%
HCA Healthcare trades at 14.7× trailing earnings, near its ten-year median. Revenue was $78B over the last twelve months, up 7% on a year earlier with a 9% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $17.3B | $17.3B | $17.5B | $17.5B | $18.3B+6% | $18.3B+6% | $18.6B+6% | $19.2B+10% | $19.5B+7% | $19.1B+4% | $20.2B+9% | |
| Cost of revenue | $2.6B | $2.7B | $10.3B | $10.5B | $10.7B+315% | $10.8B+303% | $11B+6% | $11.1B+6% | $11.3B+6% | $16.2B+51% | $17.2B+56% |
| Gross profit | $14.7B | $14.7B | $7.2B | $7B | $7.6B−49% | $7.6B−49% | $7.6B+6% | $8B+15% | $8.2B+8% | — | — |
| SG&A | $7.6B | $7.7B | $7.7B | $7.9B | $7.9B+5% | $8B+4% | $7.9B+2% | $0 | $0 | $8.3B+4% | $8.3B+6% |
| $2.8B | $2.6B | $2.7B | $2.4B | $2.8B+2% | $2.9B+12% | $3B+9% | $3B+23% | $3.2B+12% | $2.9B+0% | $3.1B+3% | |
| Interest expense | $491M | $512M | $506M | $515M | $528M+8% | $547M+7% | $568M+12% | $561M+9% | $572M+8% | $584M+7% | $599M+6% |
| Pre-tax income | $2.3B | $2.2B | $2.2B | $1.9B | $2.1B−9% | $2.3B+4% | $2.4B+8% | $2.4B+27% | $2.7B+25% | $2.3B−2% | $2.5B+3% |
| $484M | $445M | $550M | $424M | $447M−8% | $502M+13% | $524M−5% | $515M+22% | $509M+14% | $430M−14% | $564M+8% | |
| Net income | $1.6B | $1.6B | $1.5B | $1.3B | $1.4B−11% | $1.6B+1% | $1.7B+13% | $1.6B+29% | $1.9B+31% | $1.6B+1% | $1.7B+3% |
| $5.93 | $5.93 | $5.53 | $4.88 | $5.63−5% | $6.45+9% | $6.83+24% | $6.96+43% | $8.14+45% | $7.15+11% | $7.62+12% | |
| 271.2M | 268M | 264.1M | 259.9M | 255.3M−6% | 249.4M−7% | 241.9M−8% | 236.2M−9% | 230.7M−10% | 226.7M−9% | 222.8M−8% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Healthcare within ten times HCA Healthcare's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| HCAHCA Healthcare, Inc. | $95.1B | 14.7× | 13.8× | 1.2× | +7% | 8.8% | |
| ELVElevance Health Inc. | $87.7B | 18.0× | 17.6× | 0.4× | +6% | 2.5% | |
| SYKStryker Corporation | $105.6B | 28.5× | 41.2× | 4.1× | +8% | 14.4% | |
| MCKMcKesson Corporation | $106.1B | 24.4× | 25.1× | 0.3× | +9% | 1.1% | |
| MDTMedtronic plc | $109.4B | 21.1× | 28.4× | 2.9× | +10% | 13.9% | |
| CVSCVS Health Corp. | $112.5B | 23.3× | 16.2× | 0.3× | +7% | 1.2% | |
| REGNRegeneron Pharmaceuticals, Inc. | $76.4B | 18.3× | 19.8× | 4.9× | +9% | 27.9% | |
| BMYBristol-Myers Squibb Company | $122B | 13.1× | 19.9× | 2.5× | +3% | 18.9% | |
| CICigna Corporation | $73.6B | 11.5× | 16.1× | 0.3× | +8% | 2.3% | |
| VRTXVertex Pharmaceuticals Incorporated | $128.2B | 29.4× | 28.4× | 10.2× | +10% | 35.0% | |
| ISRGIntuitive Surgical, Inc. | $146.4B | 47.5× | 69.0× | 13.3× | +21% | 28.4% | |
| Peer median | $107.8B | 22.2× | 22.5× | 2.7× | +9% | 14.2% |
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .